Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) Operating Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Operating Margin for 6 consecutive years, with 43.15% as the latest value for Q4 2025.

  • Quarterly Operating Margin changed N/A to 43.15% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4.98% through Dec 2025, changed N/A year-over-year, with the annual reading at 4.94% for FY2025, 8123791.0% down from the prior year.
  • Operating Margin for Q4 2025 was 43.15% at Soleno Therapeutics, up from 33.48% in the prior quarter.
  • The five-year high for Operating Margin was 3360.98% in Q1 2025, with the low at 19.98% in Q2 2025.